[go: up one dir, main page]

WO1996008527A1 - Ortho-oligomere a empilage spirale et regulateur de systemes bio-energetiques cellulaires dans des eukaryotes et des prokaryotes bases sur ledit oligomere - Google Patents

Ortho-oligomere a empilage spirale et regulateur de systemes bio-energetiques cellulaires dans des eukaryotes et des prokaryotes bases sur ledit oligomere Download PDF

Info

Publication number
WO1996008527A1
WO1996008527A1 PCT/RU1995/000201 RU9500201W WO9608527A1 WO 1996008527 A1 WO1996008527 A1 WO 1996008527A1 RU 9500201 W RU9500201 W RU 9500201W WO 9608527 A1 WO9608527 A1 WO 9608527A1
Authority
WO
WIPO (PCT)
Prior art keywords
stacking
oligomer
cell
ορτο
spiralized
Prior art date
Application number
PCT/RU1995/000201
Other languages
English (en)
Russian (ru)
Inventor
Jury Vasilievich Medvedev
Sergei Fedorovich Enokhin
Viktor Georgievich Popov
Original Assignee
Tovarischestvo S Ogranichennoi Otvetstvennostju 'mormetall'
Aktsionernoe Obschestvo Zakrytogo Tipa 'npk Olifen'
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tovarischestvo S Ogranichennoi Otvetstvennostju 'mormetall', Aktsionernoe Obschestvo Zakrytogo Tipa 'npk Olifen' filed Critical Tovarischestvo S Ogranichennoi Otvetstvennostju 'mormetall'
Publication of WO1996008527A1 publication Critical patent/WO1996008527A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/775—Phenolic resins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • John 2.6-Di (trans.butyl-4 ⁇ letilf_nol) is affected by oxidants, these are synthesis inhibitors ⁇ and free radical processes. 5
  • the product is circulated.
  • Biological method is not installed.
  • the unit is not installed.
  • the device is operated by breathing methods.
  • the first transformer reacting with the family of variable systems: ⁇ D' ⁇ ⁇ -oxidase, succinate-system and system, (January 19, 1979) “The Possession of Assassins and Their Analogs on the Asset - 5 Parts of the Entertainment Chain”, p. 969–974).
  • ⁇ dna ⁇ narrow ⁇ aya ⁇ blas ⁇ is ⁇ lz ⁇ vaniya
  • sl ⁇ zhnaya ⁇ e ⁇ n ⁇ l ⁇ giya ⁇ lucheniya (mn ⁇ g ⁇ s ⁇ adiyny ⁇ i ⁇ liches ⁇ y sin ⁇ ez or e ⁇ s ⁇ a ⁇ shya of ⁇ li ⁇ - ⁇ ganizm ⁇ v with ⁇ sleduschim ⁇ ntsen ⁇ i ⁇ vaniem and ⁇ chis ⁇ y) ⁇ n ⁇ si ⁇ eln ⁇ nevys ⁇ aya e ⁇ e ⁇ ivn ⁇ s ⁇ za ⁇ udnyayu ⁇ is ⁇ lz ⁇ -
  • the claimed stacking - a synchronized orthopedic and regulating function of bioenergetic systems, erectile dysfunction and erythematosus are at the root of the disease.
  • the task of creating a new material is provided - a stacking-synchronized, non-resident, non-resident
  • 25 zhaschy ge ⁇ sayi ⁇ l ⁇ lineynye yad ⁇ a, ⁇ liches ⁇ v ⁇ ⁇ y ⁇ on vi ⁇ s ⁇ i ⁇ ali v ⁇ ichn ⁇ y s ⁇ u ⁇ u ⁇ y sheepvann ⁇ g ⁇ ⁇ lig ⁇ me ⁇ a ⁇ avn ⁇ ⁇ 2.6 d ⁇ 3.0 ⁇ i e ⁇ m in s ⁇ i ⁇ ali v ⁇ ichn ⁇ y s ⁇ zg ⁇ u ⁇ y ⁇ lig ⁇ me ⁇ a s ⁇ de ⁇ zhi ⁇ sya b ⁇ lee I, n ⁇ not b ⁇ lee 10 vi ⁇ v.
  • the embodiment of the claimed invention is more frequent, that the staking-personalized version of 10 causes a significant increase in the rate of 2-day-2 6- ⁇ and oxyphenylene).
  • the claimed stacking-socialized cyclic connection is a long circuit with a length of 3 to 30 small links.
  • the inventive stacking-encrypted oligomera contains cyclichexaline linear cores connected between themselves in the through-through connection _> -connection.
  • the 35 available oligomers are sourced from polyphenylene or gasoline poisons, which are quantitatively poisonous . - 5 -
  • the wrestling club has discontinued the second-hand construction of the club, which is equal to 2.6 to 3.0.
  • the invention is due to the fact that they can play the polluters, which are located at the expense of the central part of it. 3
  • these groups such as hydroxyls, alkoxy-ethers, sulfates, hydroxyalkylamines
  • octadela is shla'lin, gzksaceidlamine, ⁇ . butylamine.
  • the method of using atomic and atomic methods is based on the use of atomic potentials. ” Pa ⁇ agle ⁇ y s ⁇ i ⁇ ali, ⁇ uyu ⁇ b ⁇ azue ⁇ m ⁇ le ⁇ ula ⁇ the investigated em ⁇ g ⁇ s ⁇ edine ⁇ iya her step chisl ⁇ m ⁇ n ⁇ me ⁇ v on ⁇ din vi ⁇ and ee ⁇ adius, calculated ⁇ ⁇ dina ⁇ am s ⁇ ve ⁇ s ⁇ vuschi ⁇ ⁇ che ⁇
  • Table I provides the results of the results obtained, herewith, ⁇ - the difference in the energy of the battery and the sum of the energy of the components.
  • the transverse isomerase does not necessarily occur.
  • Aggregates are cached in a series of stacking
  • connection of the calculation method is the real ⁇ monome- Radius corner, 8 degrees apart. X on fire
  • ⁇ ⁇ ablitse 3 ⁇ veden ⁇ s ⁇ s ⁇ avl ⁇ nie s ⁇ e ⁇ alny ⁇ ⁇ a ⁇ a ⁇ e- ⁇ is ⁇ i ⁇ s ⁇ e ⁇ ssh ⁇ g-s ⁇ i ⁇ aliz ⁇ zashsh ⁇ ⁇ lig ⁇ me ⁇ v ⁇ - ⁇ enilena 0 gid ⁇ sili ⁇ vanny ⁇ 2, 3,5- ⁇ l ⁇ : _en_ya and ⁇ i ⁇ sib ⁇ nz ⁇ la.
  • P ⁇ i is ⁇ lz ⁇ vanii s ⁇ e ⁇ ing-s ⁇ i ⁇ shshz ⁇ vanny ⁇ ⁇ - ⁇ li- g ⁇ me ⁇ v of ⁇ aches ⁇ ve ⁇ egulya ⁇ a bi ⁇ en ⁇ rge ⁇ iches ⁇ i ⁇ sis ⁇ em in s ⁇ av ⁇ egulya ⁇ a na ⁇ yadu with a ⁇ ivnygl nachal ⁇ gl vzedya ⁇ vesche- s ⁇ va, ⁇ blatsaschie slugebnymi ⁇ un ⁇ tsiyami: ⁇ azbavi ⁇ eli (di ⁇ - ⁇ illi ⁇ vannaya veda, ⁇ izi ⁇ l ⁇ giches ⁇ y ⁇ as ⁇ v ⁇ and ⁇ .d.) s ⁇ u ⁇ u ⁇ b ⁇ az ⁇ va ⁇ eli ( ⁇ a ⁇ mal ), souls and ⁇ . ⁇ .
  • Zayavlyaeglye bi ⁇ l ⁇ giches ⁇ i-a ⁇ ivnye vesches ⁇ va m ⁇ gu ⁇ by ⁇ is ⁇ lz ⁇ vany in mi ⁇ bi ⁇ l ⁇ giches ⁇ y ⁇ myshlenn ⁇ s ⁇ i ⁇ a ⁇ ⁇ egulya ⁇ ⁇ s ⁇ a ⁇ le ⁇ or i ⁇ ⁇ un ⁇ tsi ⁇ ni ⁇ uschey a ⁇ ivn ⁇ s ⁇ i in ⁇ sme ⁇ i ⁇ e - in ⁇ aches ⁇ ze a ⁇ ivn ⁇ g ⁇ beginning in glazya ⁇ , ⁇ ema ⁇ , -sham ⁇ unya ⁇ ⁇ -l ⁇ s ⁇ na ⁇ , zubny ⁇ ⁇ as ⁇ a ⁇ , -in sels ⁇ m . ⁇ eyay ⁇ ve. - in the quality of supplements or products, ⁇ ⁇ - in the quality of supplements or products, ⁇ ⁇ -
  • hypoxic different genesis infectious diseases, epilepsy.
  • LB 50 when administered internally, livestock: Krumbs, children and mumps are 1350 g. / G / kg and 760-920 mg / kg - both when administered internally.
  • the inventive regulator has been studied in the experiment on microorganisms, isolated live cells of animals and people, and people, in human life, in humans.
  • an overdose device With a dose of 100 mg / l, cell mobility increases by 5 7.3 mV compared to the control population.
  • the introduction of an overdose device is a physical movement of live cells, which is associated with a change in their bioenergetic functions.
  • the claimed compound is 5.3 ⁇ 0.4 23 ⁇ 1.8 3.75 ⁇ 0. ⁇ 7 stacking-and-ligated oligon-2- (3,6-dioxi-phenylene) -sulphate
  • Table 5 The declaration of the manufacture of fumes for smoke and disinfecting isothermal media depends on the quantity of the substance - (num. 14).
  • the price was estimated at the state of the circuits of the electric power supply of the central part of the territory of the Republic of Korea and the United Kingdom.
  • the gypsy state was reached by the border of the country. Yes.
  • the stages of the transfusion of the business group entered the group enriched with acid.
  • ⁇ ⁇ ablitse 8 ⁇ eds ⁇ avleny data ⁇ s ⁇ n ⁇ sheniyu ⁇ n- tsen ⁇ atsii ⁇ islenn ⁇ y ⁇ my ⁇ av ⁇ enin ⁇ v ⁇ v ⁇ ss ⁇ an ⁇ vi- ⁇ eln ⁇ y ⁇ me ( ⁇ ⁇ ⁇ tsialn ⁇ mu pressure ⁇ isl ⁇ da ( ⁇ ⁇ ), ⁇ isli ⁇ eln ⁇ -v ⁇ ss ⁇ an ⁇ vi ⁇ eln ⁇ mu ⁇ entsialu ⁇ vi ( ⁇ ⁇ i administered 7% v ⁇ dn ⁇ g ⁇ ⁇ as ⁇ v ⁇ a occidentalvann ⁇ g ⁇ ⁇ e ⁇ a ⁇ a ⁇ a in d ⁇ - se 35 mg / kg, as well as the reduction of glucose (C hl ) and the content of small acid (C._) with the introduction of 10 mg / kg of 7 $ aqueous solution.
  • Table 3 The effect of activating the activity in the brain by filling in the box (through the ring is given)
  • Table 9 The stimulating effect of the claimed drug on the cultivation of the culture of the Sha-G7 community and the cultivation of the library on a download.
  • the antihypoxic activity of the claimed drug has been studied for various types of hypoxia in the rat and the ⁇ circle.
  • ⁇ Antiperspirants used unpredictable masses of 1.5–3.5 kg and food accents from 200–220 g.
  • Hypoxia was called-.-. Gypsy - an exposition of animals in a bar-ka-valeru at critical heights of 11-12 cm; 2. hemostatic shock - ⁇ ⁇ ⁇ think;;;;; 3. The circulatory - primitive sleepy A. r.therapy.
  • Non-oral drugs were introduced internally by the administration of Nembutal (40.0 mg / kg).
  • the development of hypothesis was encouraged by a dynamic dynamic process.
  • the claimed and ⁇ e ⁇ a ⁇ a ⁇ ⁇ e ⁇ a ⁇ a ⁇ y s ⁇ avneniya (ubi ⁇ in ⁇ n and tsi ⁇ m C) vv ⁇ dili zhiv ⁇ - nym ⁇ dn ⁇ a.z ⁇ v ⁇ vnu ⁇ ib ⁇ yushinn ⁇ sleduyuschigl ⁇ b ⁇ az ⁇ m: a) claimed ⁇ e ⁇ a ⁇ a ⁇ - s ⁇ e ⁇ ing-sshg ⁇ aliz ⁇ vanny ⁇ lig ⁇ -1,2- (3,6-di ⁇ si ⁇ enilen) - ⁇ i ⁇ sul ⁇ a ⁇ na ⁇ iya ( ⁇ 5 ) in an optimal dose of 30 mg / kg in the form of a 1% solution; b) killed in the form of a solution from a calculation of
  • Dili was the great runaway of the waters. After this, the Eglbrons were incubated at a temperature of 37 ° for 2 hours, a virus was introduced without the aid of the Castle ( ⁇ ⁇ ⁇ ) at a dose of 10 VD / ⁇ . ⁇ y. The infected embryos were additionally incubated at the age of 5–48 hours and determined the presence of viral agglutination in them. The results are presented in Table II.
  • the drugstore. ⁇ the quantity of business is the average.
  • DOSE (mg / kg) of embryo viruses / homeopathy, in the living area of the viral protection of the viral part of the stem
  • 8.0 ml of venous rounds were delivered to the hospital, which consisted of I ml of medium 199 tablets ⁇ ___ a, and a nominal number ⁇ 5017, and a flow rate of 5 min. , separated the drug layer and suspended it in 1-2 ulls of medium 199.
  • the declared impaired appliance is efficient and the best after cleaning. Actually, a staggered-extended olig- 2, 2- (3,4,6-triplexiphenylene) showed a high effeciency in the protection of the resource.
  • the on-site group of sick people made up. ⁇ 20 to 43 people.
  • the claimed regulator With the use of the claimed regulator, there was a great deal of difficulty with heavy machinery; Already in the next few hours, the indicators of central hemodynamics are improving and stabilizing, the heart rate is increasing. There is a peri- odic circulation. The consumption of acid is increased, the content of lactate and water is reduced at a lower rate, and the degree of adidosis is reduced. and hyperation.
  • the resultant compound is Olig_- ⁇ , 2- (3,4,6- ⁇ ##
  • ⁇ __ ⁇ 0) has a molecular mass of 1300, a melting point> 350 ° ⁇ .
  • the structure of the obtained compounds is analyzed by methods of the resonant resonance, the infrared and the ultraparalytic spectroscopy.
  • 1,2- (3,4,6- ⁇ -oxo-phenylated) is electrically protected by various values of ⁇ in the presence of 7 ⁇ urea.
  • Oligon-1,2- (3,4,6- ⁇ and oxi-phenyl), obtained with the aid of the United States, is listed in T.A. person 16.
  • the intact olite- ⁇ , 2- (3, 4, 6-triplexiphenyl) complex is brushed by the following characteristic areas:
  • the spacing step is 3.4 ⁇ 0.2 ⁇
  • the best result is that our connection is 850 g.
  • the resulting oligome, 2- (3,4,6-thermo-phenylated) has a very high temperature of 800, a melting point> 350 ° ⁇ . 15
  • the structure of the resulting compounds is analyzed by methods of the magnetic resonance., Infectious and ultra-sensitive spectroscopy. For the sake of comparability of the data obtained, they use tsiboxybenzene in the form of a large compound.
  • the degree of politlerization of the resulting compound is equal to 6. 20 Parameters of the strict spiral, 2- (3,4,6-transitive) are analogous to the equivalent.
  • the best compound obtained was 750.6.
  • the resulting oligomer has a molecular mass of 400, a melting point> 350 ° C. 30
  • the structure of the obtained compounds is analyzed in a similar way to I. For the compilation of the obtained data, the transmission is supported by transverse sibenzene.
  • the infectious incidence of the resulting occlusion plays the following char- acteristic areas: 825, 1085, II 90, 1415, 1496, 1496. 5 ULTRA SPECTRUM OF THE INCREASED ORGANIZATION
  • the yield of the target product is 2.645% (66 $ of theoretical value of 30 calculation results).
  • the flask is blown out and slowed down by heating and the mixture is slowed down, after which the temperature of the mixture is brought to 20 ° C.
  • the process of ligomerization is processed for 5 clay, then the alloy is cooled, the product is removed, it is electrically gummed and electromagnetized.
  • the product dries before a vacant long-standing mass. The release is 5.0 g ($ 40.3 from the theoretical). 25
  • the product has been processed by the U-, UF- and I-processes. The content of A. zot. - $ 2.54 (theoretical - $ 2.59).
  • a large oligogen aminopenil which is a 30-year self-storing-improved olymphenomenon, remains the same for the following, 8th case.
  • ⁇ ⁇ e ⁇ g ⁇ lugo ⁇ lbu equipped ⁇ b ⁇ a ⁇ nym ⁇ l ⁇ dilni- ⁇ gl, and gleshal ⁇ y ⁇ duvaegluto ine ⁇ nym gaz ⁇ m, ⁇ meschayu ⁇ ⁇ a- s ⁇ v ⁇ 35 0.4 g (5 * 10 m ⁇ l) ⁇ a ⁇ a.-benz ⁇ in ⁇ na in 40 ml of acetone ⁇ na.
  • the appliance is heated to 40 ° C and is mixed, and it is heated at the same temperature of 1.345 g. - 31 -
  • the mixture is heated to the temperature of the boiling point of the solvent and the reaction during the first hour. After leaving the factory, the product has been washed and dry and vacuumed before losing weight ..
  • Allergy-related polio which is a self-contained staking-modified code, is gradually reduced, which is equal to 5.
  • the product is processed by the methods of IS, UF, and G.S.-sectional techniques.
  • the degree of compliance is 5, the average weight is 600.
  • the nitrogen content is 2.32 $ (theoretical - 2.29 $).
  • the claimed invention finds use in the past, agricultural, in the case of medicinal products, is used, and may also be used.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'ortho-oligomère à empilage spiralé de l'invention contient des anneaux hexa-cyclolinéaires en nombres équivalents à 2,6 - 3,0 par tour de l'hélice de la structure secondaire de l'oligomère, ladite hélice contenant plus d'un tour mais pas plus de dix tours. L'invention concerne également un régulateur de systèmes bioénergétiques cellulaires dans des eukaryotes et prokaryotes contenant l'ortho-oligomère à empilage spiralé de l'invention.
PCT/RU1995/000201 1994-09-14 1995-09-12 Ortho-oligomere a empilage spirale et regulateur de systemes bio-energetiques cellulaires dans des eukaryotes et des prokaryotes bases sur ledit oligomere WO1996008527A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU94033297 1994-09-14
RU94033297 1994-09-14

Publications (1)

Publication Number Publication Date
WO1996008527A1 true WO1996008527A1 (fr) 1996-03-21

Family

ID=20160416

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU1995/000201 WO1996008527A1 (fr) 1994-09-14 1995-09-12 Ortho-oligomere a empilage spirale et regulateur de systemes bio-energetiques cellulaires dans des eukaryotes et des prokaryotes bases sur ledit oligomere

Country Status (1)

Country Link
WO (1) WO1996008527A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018758A1 (fr) * 1996-10-30 1998-05-07 Zakrytoe Aktsionernoe Obschestvo 'korporatsia Oliphen' Sel de sodium de l'acide [poly-(2,5-dihydroxyphenylene)]-4-thiosulfurique de structure lineaire, en tant que regulateur du metabolisme cellulaire, et procede de production associe
RU2120297C1 (ru) * 1997-10-31 1998-10-20 Товарищество с ограниченной ответственностью "Дека-Н" Способ нормализации обменных процессов в клетке и препарат для этих целей
RU2175317C1 (ru) * 2000-12-01 2001-10-27 Соболев Дмитрий Владимирович Натриевая соль поли(пара-дигидрокси-пара-фенилен)тиосульфокислоты, обладающая супероксидазной активностью, и способ ее получения
WO2010074591A1 (fr) 2008-12-24 2010-07-01 Закрытое Акционерное Общество "Beptekc" Amides de créatine, procédé de production, et produit possédant une action neuroprotectrice

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU598911A1 (ru) * 1976-09-23 1978-03-25 Сумгаитский Филиал Ордена Трудового Красного Знамени Института Нефтехимических Процессов Им.Акад.Ю.Г.Мамедалиева Ан Азербайджанской Сср Способ получени полигидрохинона
SU1016316A1 (ru) * 1982-01-26 1983-05-07 Институт Хлорорганического Синтеза Ан Азсср Способ получени полигидрохинона
SU1052512A1 (ru) * 1982-06-14 1983-11-07 Всесоюзный Научно-Исследовательский Институт Особо Чистых Биопрепаратов Алкиламинозамещенные производные поли-( @ -диокси- @ -фенилена) в качестве маслорастворимых антиоксидантов

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU598911A1 (ru) * 1976-09-23 1978-03-25 Сумгаитский Филиал Ордена Трудового Красного Знамени Института Нефтехимических Процессов Им.Акад.Ю.Г.Мамедалиева Ан Азербайджанской Сср Способ получени полигидрохинона
SU1016316A1 (ru) * 1982-01-26 1983-05-07 Институт Хлорорганического Синтеза Ан Азсср Способ получени полигидрохинона
SU1052512A1 (ru) * 1982-06-14 1983-11-07 Всесоюзный Научно-Исследовательский Институт Особо Чистых Биопрепаратов Алкиламинозамещенные производные поли-( @ -диокси- @ -фенилена) в качестве маслорастворимых антиоксидантов

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AKADEMIA NAUK, SSSR, (Puschino), "Reaktsii Zhivykh Sistem I Sostoyanie Energeticheskogo Obmena", 1979, pages 186-187. *
IV Konferentsia, Tezisy Dokladov, 2-4 June 1992, Onubl. 1993, RAN, Institut Khimicheskoi Fiziki, (Moscow), Vol. 16, "Bioantioksidant", pages 126-128. *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018758A1 (fr) * 1996-10-30 1998-05-07 Zakrytoe Aktsionernoe Obschestvo 'korporatsia Oliphen' Sel de sodium de l'acide [poly-(2,5-dihydroxyphenylene)]-4-thiosulfurique de structure lineaire, en tant que regulateur du metabolisme cellulaire, et procede de production associe
EA001563B1 (ru) * 1996-10-30 2001-04-23 Закрытое Акционерное Общество " Корпорация Олифен" Натриевая соль поли-(2,5-дигидрокси-фенилен)-4-тиосульфокислоты линейного строения как регулятор метаболизма клетки и способ ее получения
RU2120297C1 (ru) * 1997-10-31 1998-10-20 Товарищество с ограниченной ответственностью "Дека-Н" Способ нормализации обменных процессов в клетке и препарат для этих целей
RU2175317C1 (ru) * 2000-12-01 2001-10-27 Соболев Дмитрий Владимирович Натриевая соль поли(пара-дигидрокси-пара-фенилен)тиосульфокислоты, обладающая супероксидазной активностью, и способ ее получения
WO2010074591A1 (fr) 2008-12-24 2010-07-01 Закрытое Акционерное Общество "Beptekc" Amides de créatine, procédé de production, et produit possédant une action neuroprotectrice

Similar Documents

Publication Publication Date Title
WO1983002892A1 (fr) Preparation medicinale possedant un effet antinicotine et son procede d'obtention
WO1990008135A1 (fr) Monohydrate d'hydrochlorure d'acide ethyle ester 6-brome-5-hydroxy-4-dimethyle-aminomethyle-1-methyle-2-phenylthiomethyle indole-3-carboxylique, son procede d'obtention et preparation pharmaceutique presentant une activite antivirale, de stimulation d'interferon et d'immunomodulation basee sur ledit compose
WO1989006134A1 (fr) Preparation pharmaceutique pour traiter des etats immunodeficitaires
EP1031570A4 (fr) Modulateur immunologique ayant une activite antimicrobienne et anti-mycobacterienne, procede de production de ce modulateur et preparation pharmaceutique permettant de traiter les mycobacterioses ainsi que les affections chroniques et non specifiques des poumons, les maladies sexuellement transmissi
EP0363491A4 (en) Bacterial preparation for prophylaxis and treatment of inflammatory processes and allergic diseases
WO1996008527A1 (fr) Ortho-oligomere a empilage spirale et regulateur de systemes bio-energetiques cellulaires dans des eukaryotes et des prokaryotes bases sur ledit oligomere
WO1997037651A1 (fr) Procede de preparation d'un medicament (trecresan) ayant une action nootrope
WO2003072124A1 (fr) Methode d'induction de differentiation cellulaire
RU2105000C1 (ru) Натриевая соль [поли-(2,5-дигидрокси-фенилен)]-4-тиосульфокислоты как регулятор метаболизма клетки и способ ее получения
WO1994028153A2 (fr) Adn de faible masse moleculaire tiree de laitance d'esturgeon, procede d'obtention de l'adn et preparation pharmaceutique a base de celui-ci
Medovy et al. CYANOSIS IN INFANTS IN RURAL AREAS:(Well-Water Methæmoglobinæmia)
Mutch Synthetic magnesium trisilicate: Its action in the alimentary tract
WO2002024610A2 (fr) Procede de production d'un antineoplasique
WO2005102320A1 (fr) Medicament pour traiter des infections virales
RU2648451C1 (ru) Церебропротекторное средство
WO1997045530A1 (fr) Utilisation de souches de streptococcus faecium et composition a base de ces souches
WO1992006696A1 (fr) Procede d'obtention d'une preparation bioactive a partir du sang
WO1995008318A2 (fr) Substance medicinale a proprietes anti-infecteuses destinee a etre utilisee dans le traitement de la sterilite et dans la protection de la grossesse
EP1033369A4 (fr) DERIVES DE 5H-PYRANO [2,3-d:6,5-d']DIPYRIMIDINE AYANT UNE ACTION ANTIBACTERIENNE, ANTIVIRALE ET IMMUNO-MODULATRICE
CN111228359A (zh) 一种体内外具有抗氧化活性作用的泡桐花提取物
RU2045274C1 (ru) Витаминный чайный сбор "рябиновый" из лекарственных растений
RU2068700C1 (ru) Композиция заменителя чая
RU2052254C1 (ru) Композиция заменителя чая "ягодный"
WO2002043740A1 (fr) Procede de fabrication d'un produit antiviral immunotropique
RU2311925C1 (ru) Способ получения диагностического аллергена

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): BG BR BY CA CN JP KP MN MX UA US VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WD Withdrawal of designations after international publication

Free format text: MN,US,VN

122 Ep: pct application non-entry in european phase